A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody | Alzheimer's Research & Therapy | Full Text
Monoclonal antibodies against β-amyloid currently in phase III clinical... | Download Scientific Diagram
View of Immunotherapy Targeting Amyloid-β Peptides in Alzheimer's Disease | Exon Publications
EISAI ANNOUNCES THE START OF THE FIRST CLINICAL STUDY OF BAN2401, A NOVEL MONOCLONAL ANTIBODY TARGETING THE NEUROTOXIC PROTOFIBRILS BELIEVED TO CAUSE ALZHEIMER'S DISEASE | News Release：2010 | Eisai Co., Ltd.
The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation | Laboratory Investigation
S-1
Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment | Expert Reviews in Molecular Medicine | Cambridge Core
Advisory Council January 2018 Meeting Presentation: Overview on NIA Preclinical Pipeline | ASPE
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise - Biological Psychiatry
Biogen and Eisai try to defend Alzheimer's drug BAN2401 against skeptics | Fierce Biotech
Frontiers | Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease | Neuroscience
P4‐704: BAN2401 SHOWS STRONGER BINDING TO SOLUBLE AGGREGATED AMYLOID‐BETA SPECIES THAN ADUCANUMAB - Lannfelt - 2019 - Alzheimer's & Dementia - Wiley Online Library
BioArctic's new collaboration with Eisai on BAN2401
Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval | Semantic Scholar
Of Four Aβ Antibodies, Only Aducanumab Stems Tide of Toxic Oligomers | ALZFORUM
Biogen Results: Time To Change The Paradigm In Alzheimer's Disease (NASDAQ:BIIB) | Seeking Alpha
Lecanemab Reduces Blood Biomarkers of Alzheimer Disease - Practical Neurology
IJMS | Free Full-Text | Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease | HTML
The Development of Pharmacological Therapies for Alzheimer's Disease | SpringerLink
xmlinkhub
Biogen: BAN2401 Not A Home Run Anymore, But Still Holds Some Promise — The Non-Consensus
View of Immunotherapy Targeting Amyloid-β Peptides in Alzheimer's Disease | Exon Publications
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Alzheimer's disease: Recent treatment strategies - ScienceDirect
Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions - IOS Press
Alzheon Pipeline | Preserving Future Memories
LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
Chad Swanson, PhD, on the Promising Effect of BAN2401 on Alzheimer Disease Progression
